

Suven Life gets patent for NCE from India & New Zealand

Wednesday, April 28, 2010 16:45 IST

Our Bureau, Mumbai

Suven Life Sciences, a bio-pharmaceutical company, has received patent from New Zealand and Indian patent office for its New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid until 2024 and 2025 respectively. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzheimer's, ADHD, parkinson, schizophrenia and huntington's diseases.

With new patents, Suven has total of seven granted New Zealand product patents and 9 granted Indian product patents on NCEs. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various stages of clinical development like at phase-I or phase-II.

Suven has 12 internally discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for alzheimer's disease and schizophrenia.